Guangdong Zhongsheng Pharmaceutical (SHE:002317) obtained marketing approval for active pharmaceutical ingredient aminolevulinic acid hydrochloride from China's drug administrator.
The API is used in preparations treating genital warts, according to a Tuesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company were down 3% in recent trade.